Buprenorphine Sublingual Tablets (C-III), 2 mg, 30 Tablets (3x10), Rx only, Distributed by: American Health Packaging, Columbus, Ohio 43217, Carton NDC#: 60687-481-21, (Individual Dose NDC: 60687-481-11).
Published September 9, 2026 · Recall initiated: August 19, 2026
Summary
FDA records drug Class III recall D-0840-2026, published September 9, 2026 and initiated August 19, 2026. Recalling firm: American Health Packaging; Status: Ongoing; Reported quantity: 10,953 cartons.; Lot: Lot # 1030023, Exp Date: 06/30/2027. Class III means the product is not likely to cause adverse health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Labeling: Label Mix-up
What to do
Voluntary: Firm initiated · Letter
Get an email if BUPRENORPHINE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- BUPRENORPHINE
- Manufacturer
- American Health Packaging
- Distributor
- US Nationwide.
- Lot
- Lot # 1030023, Exp Date: 06/30/2027.
- Risk classification
- Class III
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAPrasugrel Tablets, USP, 10mg, Rx only, 30 Tablets in each bottle, Manufactured for: Mylan PharmaceuticalsSeptember 9, 2026
- FDAPrasugrel HCI, Tablets, USP, 10mg, 30-count bottle, Rx only, Marketed by: GSMS, Incorporated, Camarillo, CASeptember 9, 2026
- FDARevcovi (elapegademase-lvlr) Injection, 2.4mg/1.5mL (1.6 mg/mL), Single-Dose Vial, Rx Only, For IntramuscularSeptember 9, 2026
- FDA0.9% Sodium Chloride Injection USP 500 mL, VIAFLEX Plastic Containers, with 24 units per case. BaxterSeptember 9, 2026
- FDABuprenorphine Sublingual Tablets, 8 mg, 30 count-bottles, Rx only, Manufactured by: Sun Pharma, NDCJune 14, 2023
- FDABuprenorphine Transdermal System 5 mcg/hour, 4 transdermal systems/4 disposal units per carton, Rx Only,October 7, 2020
Questions about this recall
Was Buprenorphine Sublingual Tablets (C-III), 2 mg, 30 Tablets (3x10), Rx only, Distributed by: American Health Packaging, Columbus, Ohio 43217, Carton NDC#: 60687-481-21, (Individual Dose NDC: 60687-481-11). recalled?
Yes. FDA published recall D-0840-2026 on September 9, 2026. Reported hazard: Labeling: Label Mix-up
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: BUPRENORPHINE.